If you have a progressive condition, finding ways to look after your health to help you stay well is vitally important.Read more
Many of the conditions we support at Muscular Dystrophy UK are rare, but few are as rare as LMNA-CMD.
Professor Jenny Morgan and her team at University College London (UCL) have shown that a type of cell death called necroptosis has an important role in Duchenne muscular dystrophy.
Muscular Dystrophy UK is investing £1.2 million into 10 new research projects this year, bringing our total research portfolio to over £9.7m.
MDUK-funded researchers in collaboration with others have shown that genome editing can restore dystrophin production in dogs with Duchenne muscular dystrophy.
We’re pleased to let you know that the Institute of Neurology at University College London is recruiting for Orphazyme’s inclusion body myositis trial.
Acceleron has announced interim results from its ongoing trial testing ACE-083 in adults with CMT.
A landmark trial has shown that cognitive behavioural therapy (CBT) can benefit people with myotonic dystrophy type 1.
Acceleron has announced the FDA has granted Orphan Drug Designation to ACE-083 for the treatment of FSHD.
We are disappointed to hear that Summit Therapeutics has decided to discontinue the development of its utrophin modulator, ezutromid.
Myonexus Therapeutics gave an update on its LGMD gene therapy programmes at Sarepta’s recent R&D day.